AGA Defines How to Manage the Metabolic–Alcohol Overlap: CGH/ AGA | October 2026

What Did the Study Find?

The AGA defines MetALD as steatotic liver disease with cardiometabolic risk plus alcohol exposure of approximately 140–350 g/week in women or 210–420 g/week in men, ideally assessed over at least three months. Alcohol consumption should be evaluated at diagnosis and at least annually using nonjudgmental interviewing, validated questionnaires and, when clinically appropriate, serum or urine biomarkers.

Fibrosis assessment should follow a staged noninvasive pathway—typically FIB-4 followed by transient elastography or ELF when indicated—while recognizing that active alcohol-related inflammation can transiently increase liver stiffness. Management must address both causal domains: alcohol reduction or abstinence with evidence-based treatment for alcohol-use disorder, alongside weight management, exercise and aggressive treatment of diabetes, dyslipidaemia and hypertension. Nutritional assessment and replacement of thiamine, folate and vitamin D are also advised. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

Labelling these patients simply as MASLD risks minimizing alcohol exposure; labelling them only as alcohol-related disease can overlook modifiable metabolic risk. These are expert recommendations without formal systematic review or evidence grading, and MetALD-specific drug trials remain limited.

GastroAGI Takeaway

MetALD requires dual treatment: reducing alcohol without stigma while managing obesity, diabetes and fibrosis risk with equal intensity.